La cadena de opciones muestra datos clave de las opciones de acciones de China SXT Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para China SXT Pharmaceuticals..

China SXT Pharmaceuticals (NASDAQ:SXTC) Bolsa, Cadena de Opciones

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals Inc

News

Offerings

EONR

Eon Resources Files For Offering Up To 7.8M Shares Of Class A Common Stock By Selling Security Holders

Vasta Platform (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) reported quarterly earnings of $0.05 per share. This is a 16.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $73.49 million in sales this quarter. This is a 21.04 percent decrease over sales of $93.08 million the same period last year.

Earnings

VSTA

Vasta Platform Q1 Adj. EPS $0.05, Sales $73.49M

UBS analyst Steven Fisher maintains Tutor Perini (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) with a Buy and raises the price target from $40 to $41.

Price Target

Analyst Ratings

UBS Maintains Buy on Tutor Perini, Raises Price Target to $41

UBS analyst Jay Sole maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Neutral and raises the price target from $68 to $73.

UBS Maintains Neutral on Tapestry, Raises Price Target to $73

UBS analyst Peter Grom maintains Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) with a Buy and raises the price target from $76 to $78.

UBS Maintains Buy on Spectrum Brands Holdings, Raises Price Target to $78

UBS analyst Jay Sole maintains Wolverine World Wide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WWW#NYSE">WWW</a>) with a Buy and raises the price target from $18 to $22.

UBS Maintains Buy on Wolverine World Wide, Raises Price Target to $22

General

CXAI

CXApp Registers Resale Of Up To 18.5M Shares Of Common Stock By Selling Securityholders, Including 80,000 Shares Issued To Avondale Capital And Up To 18.42M Shares Issuable Under A $20M Securities Purchase Agreement

UBS analyst Timothy Chiodo maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Neutral and lowers the price target from $62 to $56.

AFRM

UBS Maintains Neutral on Affirm Holdings, Lowers Price Target to $56

Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) has outperformed the market over the past 5 years by 20.51% on an annualized basis producing an average annual return of 35.02%. Currently, Dell Technologies has a market capitalization of $66.92 billion. 
Buying $1000 In DELL: If an investor had bought $1000 of DELL stock 5 years ago, it would be worth $4,371.54 today based on a price of $95.89 for DELL at the time of writing.
<h3>Dell Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746827112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

DELL

$1000 Invested In Dell Technologies 5 Years Ago Would Be Worth This Much Today

UBS analyst Taylor McGinnis maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and raises the price target from $675 to $820.

HUBS

UBS Maintains Buy on HubSpot, Raises Price Target to $820

UBS analyst Timothy Chiodo maintains Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) with a Neutral and lowers the price target from $125 to $110.

SHOP

UBS Maintains Neutral on Shopify, Lowers Price Target to $110

UBS analyst Kunal Madhukar maintains RealReal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>) with a Neutral and raises the price target from $6 to $7.

REAL

UBS Maintains Neutral on RealReal, Raises Price Target to $7

UBS analyst A.J. Rice maintains Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) with a Sell and raises the price target from $4.5 to $5.

AVAH

UBS Maintains Sell on Aveanna Healthcare Hldgs, Raises Price Target to $5

CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) today announced it has reached a tentative agreement with the Brotherhood of Locomotive Engineers and Trainmen (BLET) on a new five-year single-system agreement covering approximately 3,400 locomotive engineers.
This is the first agreement reached by a Class I freight railroad with BLET, and it continues CSX's industry-leading transformational approach to collective bargaining in the rail industry.

Contracts

CSX Announces It Has Reached A Tentative Agreement With The Brotherhood Of Locomotive Engineers And Trainmen On A New 5- year Single-System Agreement Covering ~3,400 Locomotive Engineers

UBS analyst Kunal Madhukar maintains Cars.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARS#NYSE">CARS</a>) with a Neutral and lowers the price target from $13 to $12.

CARS

UBS Maintains Neutral on Cars.com, Lowers Price Target to $12

Chicago Rivet &amp; Machine (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVR#AMEX">CVR</a>) reported quarterly earnings of $0.42 per share. This is a 158.33 percent increase over losses of $(0.72) per share from the same period last year. The company reported $7.25 million in sales this quarter. This is a 7.74 percent decrease over sales of $7.85 million the same period last year.

Chicago Rivet & Machine Q1 EPS $0.42 Up From $(0.72) YoY, Sales $7.25M Down From $7.85M YoY

UBS analyst Batya Levi maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Buy and lowers the price target from $41 to $38.

UBS Maintains Buy on Warner Music Gr, Lowers Price Target to $38

Alliant Energy Files For Common Stock Offering Of Up To $1.3B

UBS analyst Kunal Madhukar maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Neutral and raises the price target from $29 to $33.

CARG

UBS Maintains Neutral on CarGurus, Raises Price Target to $33

UBS analyst Stephen Ju maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Neutral and raises the price target from $12 to $14.

Comments

China SXT Pharmaceuticals

China SXT Pharmaceuticals (SXTC) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL